China Biopharma Inc. (CHBO) Financials Nov 14, 201
Post# of 250675
Posted On: 11/17/2014 2:18:29 AM
China Biopharma Inc. (CHBO) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for China Biopharma Inc.
Fiscal year is January-December. All values USD millions. 2004 2005 2006 2007 2008 5-year trend
Sales/Revenue 312,899 380,519 1.2M 688,705 5.54M
Cost of Goods Sold (COGS) incl. D&A 232,621 272,017 1.11M 657,322 5.35M
COGS excluding D&A 124,431 136,017 1.07M 615,129 5.33M
Depreciation & Amortization Expense 108,190 136,000 38,811 42,193 17,826
Depreciation 108,190 136,000 38,811 42,193 17,826
Amortization of Intangibles - - - - -
Gross Income 80,278 108,502 89,088 31,383 192,398
2004 2005 2006 2007 2008 5-year trend
SG&A Expense 1.51M 2.84M 3.75M 1.38M 694,999
Research & Development 432,144 611,362 0 0 0
Other SG&A 1.08M 2.23M 3.75M 1.38M 694,999
Other Operating Expense 0 0 0 0 461,568
Unusual Expense 0 0 0 304,094 0
EBIT after Unusual Expense 0 0 0 (304,094) 0
Non Operating Income/Expense 4,810 216,247 (1.06M) 99,164 143,657
Non-Operating Interest Income 3,695 420 0 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense - - - 205,278 61,739
Gross Interest Expense - - - 205,278 61,739
Interest Capitalized 0 0 0 0 0
Pretax Income (1.42M) (2.52M) (4.73M) (1.76M) (882,251)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates (20,796) 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.45M) (2.52M) (4.73M) (1.76M) (882,251)
Minority Interest Expense 0 0 0 (105,740) 47,836
Net Income (1.45M) (2.52M) (4.73M) (1.65M) (930,087)
Extraordinaries & Discontinued Operations 0 (324,167) 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 (324,167) 0 0 0
Cumulative Effect - Accounting Chg 0 (324,167) 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (1.45M) (2.84M) (4.73M) (1.65M) (930,087)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (1.45M) (2.52M) (4.73M) (1.65M) (930,087)
EPS (Basic) (2.00) (3.00) (6.00) (1.00) (0.22)
Basic Shares Outstanding 741,201 815,283 855,200 1.12M 4.32M
EPS (Diluted) (2.00) (3.00) (6.00) (1.00) (0.22)
Diluted Shares Outstanding 741,201 815,283 855,200 1.12M 4.32M
EBITDA (1.33M) (2.6M) (3.62M) (1.31M) (946,343)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for China Biopharma Inc.
Fiscal year is January-December. All values USD millions. 2004 2005 2006 2007 2008 5-year trend
Sales/Revenue 312,899 380,519 1.2M 688,705 5.54M
Cost of Goods Sold (COGS) incl. D&A 232,621 272,017 1.11M 657,322 5.35M
COGS excluding D&A 124,431 136,017 1.07M 615,129 5.33M
Depreciation & Amortization Expense 108,190 136,000 38,811 42,193 17,826
Depreciation 108,190 136,000 38,811 42,193 17,826
Amortization of Intangibles - - - - -
Gross Income 80,278 108,502 89,088 31,383 192,398
2004 2005 2006 2007 2008 5-year trend
SG&A Expense 1.51M 2.84M 3.75M 1.38M 694,999
Research & Development 432,144 611,362 0 0 0
Other SG&A 1.08M 2.23M 3.75M 1.38M 694,999
Other Operating Expense 0 0 0 0 461,568
Unusual Expense 0 0 0 304,094 0
EBIT after Unusual Expense 0 0 0 (304,094) 0
Non Operating Income/Expense 4,810 216,247 (1.06M) 99,164 143,657
Non-Operating Interest Income 3,695 420 0 0 0
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense - - - 205,278 61,739
Gross Interest Expense - - - 205,278 61,739
Interest Capitalized 0 0 0 0 0
Pretax Income (1.42M) (2.52M) (4.73M) (1.76M) (882,251)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 0 0
Income Tax - Current Foreign 0 0 0 0 0
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 0 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates (20,796) 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (1.45M) (2.52M) (4.73M) (1.76M) (882,251)
Minority Interest Expense 0 0 0 (105,740) 47,836
Net Income (1.45M) (2.52M) (4.73M) (1.65M) (930,087)
Extraordinaries & Discontinued Operations 0 (324,167) 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 (324,167) 0 0 0
Cumulative Effect - Accounting Chg 0 (324,167) 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (1.45M) (2.84M) (4.73M) (1.65M) (930,087)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (1.45M) (2.52M) (4.73M) (1.65M) (930,087)
EPS (Basic) (2.00) (3.00) (6.00) (1.00) (0.22)
Basic Shares Outstanding 741,201 815,283 855,200 1.12M 4.32M
EPS (Diluted) (2.00) (3.00) (6.00) (1.00) (0.22)
Diluted Shares Outstanding 741,201 815,283 855,200 1.12M 4.32M
EBITDA (1.33M) (2.6M) (3.62M) (1.31M) (946,343)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)